|
WO2019204583A1
|
|
Antifungal formulations for pulmonary administration comprising itraconazole
|
|
WO2019204597A1
|
|
Methods of treating fungal infections
|
|
US2019167579A1
|
|
Itraconazole dry powders
|
|
KR20190068591A
|
|
Antifungal dry powder
|
|
WO2016057644A1
|
|
Improved stability of dry powders containing tiotropium and amino acid
|
|
CA2963666A1
|
|
Formulations containing tiotropium, amino acid and acid and methods thereof
|
|
NZ629722A
|
|
Inhalable dry powders
|
|
NZ705080A
|
|
Monovalent metal cation dry powders for inhalation
|
|
EP3470057A1
|
|
Cationic dry powders comprising magnesium salt
|
|
NZ705049A
|
|
Respirable cationic dry powders for delivery to the respiratory tract
|
|
NZ703804A
|
|
Dry powder formulations and methods for treating pulmonary diseases
|
|
AU2011296343A1
|
|
Dry powder formulations and methods for treating pulmonary diseases
|
|
AU2010229668A1
|
|
Dry powder formulations and methods for treating pulmonary diseases
|
